Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [11C]raclopride and high-resolution positron emission tomography

NeuroImage

Volumn 82, Issue , 2013, Pages 252-259

  Alakurtti, Kati ^a   Johansson, Jarkko J ^a   Tuokkola, Terhi ^a   Någren, Kjell ^b   Rinne, Juha O ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

11C raclopride; D2 3 receptors; Dopamine; Gradient; PET; Ventral striatum

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RACLOPRIDE C 11;

ADULT; ARTICLE; CAUDATE NUCLEUS; CORPUS STRIATUM; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; MALE; NEUROPHYSIOLOGY; NORMAL HUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PUTAMEN; RECEPTOR BINDING; ROSTROCAUDAL AXIS; STRIATE CORTEX;

[(11)C]RACLOPRIDE; AC; ANTERIOR COMMISSURE; ANTERIOR-POSTERIOR; AP; BP(ND); D(2/3) RECEPTORS; DA; DAT; DCA; DOPAMINE; DOPAMINE TRANSPORTER; DORSAL CAUDATE NUCLEUS; DORSAL PUTAMEN; DPU; GRADIENT; HIGH-RESOLUTION RESEARCH TOMOGRAPHY; HRRT; MSA; MULTIPLE SYSTEM ATROPHY; NON-DISPLACEABLE BINDING POTENTIAL; PARTIAL VOLUME EFFECT; PET; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; PSP; PVE; REGION OF INTEREST; ROI; SIMPLIFIED REFERENCE TISSUE MODEL; SRTM; TAC; TIME-ACTIVITY CURVE; VENTRAL STRIATUM; VST;

BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; CORPUS STRIATUM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; YOUNG ADULT;

EID: 84879726526     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.05.091     Document Type: Article

References (59)

1. 11C]raclopride with high-resolution positron emission tomography. J. Cereb. Blood Flow Metab. 2011, 31:155-165.
2. 11C]-raclopride. Ann. N. Y. Acad. Sci. 1993, 695:81-85.
3. Antonini A., Leenders K.L., Vontobel P., Maguire R.P., Missimer J., Psylla M., Günther I. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997, 120(Pt 12):2187-2195.
4. Bäckman L., Ginovart N., Dixon R.A., Wahlin T.B., Wahlin A., Halldin C., Farde L. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am. J. Psychiatry 2000, 157:635-637.
5. Bäckman L., Nyberg L., Lindenberger U., Li S.-C., Farde L. The correlative triad among aging, dopamine, and cognition: current status and future prospects. Neurosci. Biobehav. Rev. 2006, 30:791-807.
6. Belin D., Everitt B.J. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2008, 57:432-441.
7. 11C-raclopride and positron emission tomography. Ann. Neurol. 1992, 31:184-192.
8. Brücke T., Asenbaum S., Pirker W., Djamshidian S., Wenger S., Wöber C., Müller C., Podreka I. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J. Neural Transm. Suppl. 1997, 50:9-24.
9. 2 receptors in normal human brain with [3H]N-n-propylnorapomorphine. Brain Res. 1986, 375:135-149.
10. 2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. NeuroImage 2008, 40:1287-1295.
11. Comtat C., Bataille F., Michel C., Jones J.P., Sibomana M., Janeiro L., Trebossen R. OSEM-3D reconstruction strategies for the ECAT HRRT. Nuclear Science Symposium Conference Record, 2004 IEEE 2004, vol. 6:3492-3496.
12. Comtat C., Sureau F.C., Sibomana M., Hong I.K., Sjoholm N., Trebossen R. Image based resolution modeling for the HRRT OSEM reconstructions software. NSS '08. IEEE 2008, 4120-4123.
13. De Jong H.W.A.M., Van Velden F.H.P., Kloet R.W., Buijs F.L., Boellaard R., Lammertsma A.A. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys. Med. Biol. 2007, 52:1505-1526.
14. Deep P., Kuwabara H., Gjedde A., Cumming P. The kinetic behaviour of [3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms. J. Neurosci. Methods 1997, 78:157-168.
15. DeLong M.R. The neurophysiologic basis of abnormal movements in basal ganglia disorders. Neurobehav. Toxicol. Teratol. 1983, 5:611-616.
16. Evarts E.V., Wise S.P. Basal ganglia outputs and motor control. CIBA Found. Symp. 1984, 107:83-102.
17. Floresco S.B., St Onge J.R., Ghods-Sharifi S., Winstanley C.A. Cortico-limbic-striatal circuits subserving different forms of cost-benefit decision making. Cogn. Affect. Behav. Neurosci. 2008, 8:375-389.
18. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 1992, 15:133-139.
19. Gerfen C.R., McGinty J.F., Young W.S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 1991, 11:1016-1031.
20. Ghaemi M., Hilker R., Rudolf J., Sobesky J., Heiss W.-D. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J. Neurol. Neurosurg. Psychiatry 2002, 73:517-523.
21. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
22. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997, 6:279-287.
23. 2 receptor expressing neurons. Neuropsychopharmacology 1999, 20:60-80.
24. Haber S.N. The primate basal ganglia: parallel and integrative networks. J. Chem. Neuroanat. 2003, 26:317-330.
25. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994, 11:245-256.
26. 11C-raclopride. Nucl. Med. Commun. 2003, 24:1207-1214.
27. 2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res. 2006, 146:13-20.
28. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.-C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
29. 11C]raclopride: PET with anatomic standardization technique. NeuroImage 1999, 9:235-242.
30. Ito H., Takahashi H., Arakawa R., Takano H., Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. NeuroImage 2008, 39:555-565.
31. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000, 96:451-474.
32. Kaasinen V., Rinne J.O. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci. Biobehav. Rev. 2002, 26:785-793.
33. Kim J.-H., Son Y.-D., Kim H.-K., Lee S.-Y., Cho S.-E., Kim Y.-B., Cho Z.-H. Effects of age on dopamine D(2) receptor availability in striatal subdivisions: a high-resolution positron emission tomography study. Eur. Neuropsychopharmacol. 2011, 21:885-891.
34. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
35. Kuepper R., Skinbjerg M., Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb. Exp. Pharmacol. 2012, 1-26.
36. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 1996, 4:153-158.
37. 3 receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res. 1993, 18:187-192.
38. 11C]methyl triflate. J. Labelled Comp. Radiopharm. 1999, 42:1183-1193.
39. 11C]methane. Appl. Radiat. Isot. 1997, 48:153-157.
40. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.-R., Huang Y., Cooper T., Kegeles L., Zarahn E., Abi-Dargham A., Haber S.N., Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab. 2003, 23:285-300.
41. Martinez D., Gil R., Slifstein M., Hwang D.-R., Huang Y., Perez A., Kegeles L., Talbot P., Evans S., Krystal J., Laruelle M., Abi-Dargham A. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 2005, 58:779-786.
42. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., Huang Y., Simpson N., Ngo K., Van Heertum R., Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 2001, 21:1034-1057.
43. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 1984, 15:217-227.
44. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
45. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11271-11275.
46. 11C]methane. J. Labelled Comp. Radiopharm. 2003, 46(Suppl. 1):S76.
47. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67:53-83.
48. 11C]FLB 457. NeuroImage 1999, 10:666-674.
49. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev. 1995, 20:91-127.
50. 3 receptor binding or dopamine. Neuroscience 1999, 90:433-445.
51. Rinne J.O., Laihinen A., Lönnberg P., Marjamäki P., Rinne U.K. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res. 1991, 556:117-122.
52. 11C]raclopride. J. Cereb. Blood Flow Metab. 1993, 13:310-314.
53. 2/3-binding sites in the basal ganglia of pig and monkey measured by PET. NeuroImage 2004, 22:1076-1083.
54. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Becker L.E., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., Watanabe S. Human brain dopamine receptors in children and aging adults. Synapse 1987, 1:399-404.
55. 3) as a target for neuroleptics. Nature 1990, 347:146-151.
56. Volkow N.D., Fowler J.S., Wang G.J., Dewey S.L., Schlyer D., MacGregor R., Logan J., Alexoff D., Shea C., Hitzemann R. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J. Nucl. Med. 1993, 34:609-613.
57. 2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993, 14:169-177.
58. Volkow N.D., Gur R.C., Wang G.J., Fowler J.S., Moberg P.J., Ding Y.S., Hitzemann R., Smith G., Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 1998, 155:344-349.
59. 2 receptor levels. Am. J. Psychiatry 1999, 156:1440-1443.